Evidence map›Paper›PMID 38521535›Full record

Trial reportBMJ open2024

Return of participant-level clinical trial results to participants: pilot of a simplified centralised approach.

Eric Hoffman, Suzanne Gaglianone, Rahel Ketema, Wangshu Tu, Holly Peay, Paula Clemens, Utkarsh Dang, Laurie Conklin

2 registry-linked trialsAbstract readClinical Trial, Phase II
In one paragraph

Trial report in BMJ open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02760264 phase2completednot on this map

A Phase IIa Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)

TypeinterventionalSponsorReveraGen BioPharma, Inc.Ran2016 to 2018Enrolled48ConditionsDuchenne Muscular DystrophyArmsVamorolone 0.25 mg/kg/day, Vamorolone 0.75 mg/kg/day, Vamorolone 2.0 mg/kg/day, Vamorolone 6.0 mg/kg/day
NCT02760277 phase2completednot on this map

A Phase II Open-label, Multicenter Extension Study to Assess the Long-term Safety and Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)

TypeinterventionalSponsorReveraGen BioPharma, Inc.Ran2016 to 2018Enrolled48ConditionsDuchenne Muscular DystrophyArmsVamorolone 0.25 mg/day/day, Vamorolone 0.75 mg/day/day, Vamorolone 2.0 mg/day/day, Vamorolone 6.0 mg/day/day
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Eric HoffmanPharmaceutical Sciences, State University of New York at Binghamton, Binghamton, New York, USA ehoffman@binghamton.edu.ORCID 0000-0001-6470-5139
Suzanne GaglianoneReveraGen BioPharma, Rockville, Maryland, USA.
Rahel KetemaReveraGen BioPharma, Rockville, Maryland, USA.
Wangshu TuCarleton University, Ottawa, Ontario, Canada.
Holly PeayRTI International, Research Triangle Park, North Carolina, USA.
Paula ClemensUniversity of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Utkarsh DangCarleton University, Ottawa, Ontario, Canada.
Laurie ConklinReveraGen BioPharma, Rockville, Maryland, USA.

Funding

Pivotal trial of vamorolone in Duchenne muscular dystrophyR44NS095423 · NINDS · REVERAGEN BIOPHARMA, INC. · PI CLEMENS, PAULA R, HOFFMAN, ERIC P. · 2016 to 2019
$6.1M
NINDS NIH HHS R44 NS095423
6 · The paper itself

Abstract

objectivesPublic access databases such as clinicaltrials.gov achieve dissemination of clinical trial design and aggregated study results. However, return of participant-level data is rarely done. A key barrier includes the proprietary ownership of data by the sponsor. Additionally, investigators may not have access to centralised data, and per International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Good Clinical Practice, must maintain the confidentiality of participants. This study piloted an approach to return both individual and aggregate clinical trial data to parents of children participating in a series of open-label clinical trials. SETTING AND

designA small biotech company obtained central ethics approval (centralised institutional review board [IRB], non-exempt). The study was advertised via parent advocacy groups. Parents of trial participants were offered the option to contact an employee (coordinator) within the company, requesting return of their child's study results. Ethics approval covered participation in six countries. The study focused on the sequential clinical trials of vamorolone VBP15-002 (NCT02760264) and VBP15-003 (NCT02760277) (post-results).

interventionsContact initiated by the parent enabled the coordinator to obtain informed consent (and separate General Data Protection Regulations consent), with phone translation when needed. Using date of birth and study site location provided by the parent, the data manager reported the participant number to the coordinator. The coordinator retrieved and compiled data, along with an aggregate summary, which was mailed via a password protected and encrypted memory device to the parent. Prereturn and postreturn surveys were sent to consented parents (n=19; 40% of 48 total trial participants) and investigators.

resultsPrereturn surveys indicated a request for as much data as offered, in all formats offered. Postreturn survey showed high satisfaction with the process and data returned. Survey of the physician site investigators (n=10; 100% participation of investigators) voiced general satisfaction with the process, with some reservations.

conclusionsThis pilot study demonstrates an innovative, cost-effective, centralised and labour conservative approach to return of participant-level and aggregate data to participants in studies.

Indexed as

Informed ConsentChildClinical Trials as TopicHumansPilot ProjectsSurveys and QuestionnairesClinical TrialETHICS (see Medical Ethics)Health LiteracyPatient Satisfaction

Identifiers

PMID38521535
PMCPMC10961551

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.